Diagnostic potential of tumor DNA from ovarian cyst fluid
10.7554/eLife.15175.001 We determined whether the mutations found in ovarian cancers
could be identified in the patients' ovarian cyst fluids. Tumor-specific mutations were …
could be identified in the patients' ovarian cyst fluids. Tumor-specific mutations were …
A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from …
…, JD Brenton, F Daley, B Kristjansdottir, C Mateoiu… - Modern …, 2019 - nature.com
Primary ovarian mucinous tumors can be difficult to distinguish from metastatic gastrointestinal
neoplasms by histology alone. The expected immunoprofile of a suspected metastatic …
neoplasms by histology alone. The expected immunoprofile of a suspected metastatic …
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study
…, TA Longacre, M Lycke, C Mateoiu… - The Journal of …, 2023 - Wiley Online Library
Our objective was to test whether p53 expression status is associated with survival for
women diagnosed with the most common ovarian carcinoma histotypes (high‐grade serous …
women diagnosed with the most common ovarian carcinoma histotypes (high‐grade serous …
Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in …
…, LR Wilkens, MT Goodman, C Mateoiu… - The Journal of …, 2022 - Wiley Online Library
ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an
important tumour suppressor role, and is considered prognostic in several malignancies. …
important tumour suppressor role, and is considered prognostic in several malignancies. …
Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses
…, PDP Pharoah, JD Brenton, W Sieh, C Mateoiu… - Modern …, 2021 - nature.com
TP53 mutations are implicated in the progression of mucinous borderline tumors (MBOT) to
mucinous ovarian carcinomas (MOC). Optimized immunohistochemistry (IHC) for TP53 has …
mucinous ovarian carcinomas (MOC). Optimized immunohistochemistry (IHC) for TP53 has …
[HTML][HTML] Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b
K Levan, M Mehryar, C Mateoiu, P Albertsson, T Bäck… - BMC cancer, 2017 - Springer
Background To characterize the expression of the membrane transporter NaPi2b and antigen
targeted by the MX35 antibody in ovarian tumor samples. The current interest to develop …
targeted by the MX35 antibody in ovarian tumor samples. The current interest to develop …
[HTML][HTML] Increased disease-free and relative survival in advanced ovarian cancer after centralized primary treatment
C Palmqvist, C Staf, C Mateoiu, M Johansson… - Gynecologic …, 2020 - Elsevier
Objective To analyze 5-year disease-free survival (DFS) and relative survival (RS) before
and after the 2011 implementation of centralized primary treatment of patients with advanced …
and after the 2011 implementation of centralized primary treatment of patients with advanced …
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma
…, N Sasamoto, L Van-Wagensveld, M Lycke, C Mateoiu… - Virchows Archiv, 2022 - Springer
Tubo-ovarian high-grade serous carcinomas (HGSC) are highly proliferative neoplasms
that generally respond well to platinum/taxane chemotherapy. We recently identified …
that generally respond well to platinum/taxane chemotherapy. We recently identified …
Gene-expression profiling of mucinous ovarian tumors and comparison with upper and lower gastrointestinal tumors identifies markers associated with adverse …
…, A Linder, J Lubiński, S Mahale, C Mateoiu… - Clinical Cancer …, 2022 - AACR
Purpose: Advanced-stage mucinous ovarian carcinoma (MOC) has poor chemotherapy
response and prognosis and lacks biomarkers to aid stage I adjuvant treatment. Differentiating …
response and prognosis and lacks biomarkers to aid stage I adjuvant treatment. Differentiating …
[HTML][HTML] Concurrent RB1 loss and BRCA-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma
…, ND Le, M Lener, J Lester, J Lubiński, C Mateoiu… - medRxiv, 2023 - ncbi.nlm.nih.gov
Background: Somatic loss of the tumour suppressor RB1 is a common event in tubo-ovarian
high-grade serous carcinoma (HGSC), which frequently co-occurs with alterations in …
high-grade serous carcinoma (HGSC), which frequently co-occurs with alterations in …